Innodem Neurosciences names Chief Medical Officer
by CM staff
Dr. Giacomini is a neurologist specializing in multiple sclerosis and neuroinflammatory disorders, as well as advanced neuroimaging techniques.
(CNW Group/Innodem Neurosciences)
MONTREAL — Innodem Neurosciences, a company in digital health and the convergence of neuroscience, pharmaceuticals and AI, appoints Dr. Paul Giacomini, M.D., FRCPC, as the company’s Chief Medical Officer.
Dr. Giacomini is a neurologist specializing in multiple sclerosis and neuroinflammatory disorders, as well as advanced neuroimaging techniques. He is the Director of The Neuro’s Multiple Sclerosis Clinic, Associate Professor of Neurology and Neurosurgery at McGill University, and attending physician at the Montreal Neurological Institute (The Neuro) and the McGill University Health Centre (MUHC).
In addition to his clinical practice, Dr. Giacomini was the main researcher in numerous clinical trials evaluating new therapies for various neuroinflammatory diseases. For example, he is the founder and co-director of the DEMySTIFI data project (Data Extraction in Multiple Sclerosis To Inform Future Interventions), a database compiling clinical, imaging, biological and genetic data to better understand treatment response and disease progression. He is also involved in imaging research using artificial intelligence to predict treatment response in neuroinflammatory disorders, with the aim of guiding personalized therapeutic decisions.
“I’m delighted to be joining a company where I’ll be able to apply my expertise to the development of a technology that has unique potential to make the detection and monitoring of neurological diseases easier, more efficient and more accessible, all using a simple mobile app. I’m excited by the potential of this sensitive, accurate and scalable biomarker technology to democratize diagnostic support for neurodegenerative and mental diseases.”
Innodem Neurosciences’ patented eye movement detection technology consists of an application which, subject to Health Canada approval, will transform an iPad Pro into a medical device linked to a cloud-based artificial intelligence infrastructure.
The experimental application enables a series of non-invasive tests to be carried out in just a few minutes, recording and compiling the user’s eye movements. Analysis of this data will enable specialists to facilitate the diagnosis and monitoring of neurodegenerative and mental illnesses. Innodem recently signed a multi-year commercial framework agreement with Novartis Pharma Canada to support its ongoing efforts.
